Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Insomnia Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 201-J

    Insomnia Agents Post-Limit Prior Authorization Criteria

    Customize your policy alerts

    Sign up for cvs_caremark Policy 201-J alerts

    Get alerted when Policy 201-J changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs post-limit prior authorization for specified prescription insomnia agents, including initial and continuation therapy requirements and quantity limits. It applies to providers requesting coverage for patients treated for insomnia.

    Policy Summary
    PayerCVS Caremark
    PolicyInsomnia Agents Post-Limit Prior Authorization Criteria
    Policy CodePolicy 201-J
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor continuation therapy, document a positive response to treatment, assess the need for continued therapy, and address contributing factors to insomnia.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30 tablets/25 daysStandard quantity limit
    60 capsules/25 daysZaleplon quantity limit
    No post-limit quantitiesSpecified benzodiazepines
    6 monthsInitial approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Continuation approval duration
    7-10 daysShort-term treatment duration

    Coverage Criteria

    Initial Therapy

    Authorization may be granted when the requested drug is prescribed for insomnia and the following criterion is met.

    Initial therapy: Potential factors contributing to sleep disturbances have been addressed or are currently being addressed, including inappropriate sleep hygiene, sleep-environment issues, and treatable medical or psychiatric disorders that are comorbid with insomnia.

    Continuation Therapy

    Authorization may be granted when the requested drug is prescribed for insomnia and ALL of the following criteria are met.

    Continuation therapy

    • Positive response: The patient has achieved or maintained a positive response to treatment from baseline.
    • Continued-therapy assessment: The patient's need for continued therapy has been assessed.
    • Contributing factors addressed: Potential factors contributing to sleep disturbances continue to be addressed, including inappropriate sleep hygiene, sleep-environment issues, and treatable medical or psychiatric comorbid disorders.

    Insomnia continuation therapy

    Continuation authorization may be granted when all of the following are met.

    Continuation therapy criteria

    • Clinical response and ongoing management

      • Positive response: The patient has achieved or maintained a positive response to treatment from baseline.
      • Continued-therapy assessment: The patient's need for continued therapy has been assessed.
      • Contributing factors addressed: Potential factors contributing to sleep disturbances continue to be addressed, including inappropriate sleep hygiene, sleep-environment issues, and treatable medical or psychiatric comorbid disorders.

    Edluar, zolpidem tartrate sublingual tablets (generic Intermezzo), ZolpiMist, Belsomra, Dayvigo, and Quviviq are not included in these criteria. Refer these products to the applicable separate insomnia prior authorization criteria.

    No post-limit quantities are available for Doral, estazolam, flurazepam, Halcion, or Restoril.

    Provider Actions

    Documentation Required

    Initial Insomnia Authorization

    Authorization may be granted when the requested drug is prescribed for insomnia and potential factors contributing to sleep disturbances have been addressed or are currently being addressed.

    • Address inappropriate sleep hygiene and sleep-environment issues.
    • Address treatable medical or psychiatric disorders that are comorbid with insomnia.
    Documentation Required

    Continuation Therapy Requirements

    Continuation therapy authorization may be granted when the patient has responded positively to treatment from baseline, the ongoing need for therapy has been assessed, and contributing factors continue to be addressed.

    • Document a positive response to treatment from baseline.
    • Assess and document the patient's need for continued therapy.
    • Continue addressing sleep hygiene, sleep-environment issues, and treatable medical or psychiatric comorbid disorders.

    Policy Background

    This policy addresses prescription agents used to treat insomnia, including difficulty with sleep onset or initiation, difficulty maintaining sleep, frequent nocturnal awakenings, and early morning awakenings. Several agents are intended for short-term treatment; management also emphasizes addressing sleep hygiene, the sleep environment, and coexisting medical or psychiatric conditions that may contribute to sleep disturbance.

    Initial Therapy

    Insomnia Initial Therapy

    Authorization may be granted when the requested drug is prescribed for insomnia and the following criterion is met.

    Initial therapy: Potential factors contributing to sleep disturbances have been addressed or are currently being addressed, including inappropriate sleep hygiene, sleep-environment issues, and treatable medical or psychiatric disorders that are comorbid with insomnia.

    Continuation Therapy

    Insomnia Continuation Therapy

    Authorization may be granted when the requested drug is being prescribed for insomnia and ALL of the following criteria are met.

    Continuation therapy

    • Positive response: The patient has achieved or maintained a positive response to treatment from baseline.
    • Continued-therapy assessment: The patient's need for continued therapy has been assessed.
    • Contributing factors addressed: Potential factors contributing to sleep disturbances continue to be addressed, including inappropriate sleep hygiene, sleep-environment issues, and treatable medical or psychiatric comorbid disorders.

    Insomnia continuation therapy

    Quantity Limits and Post-Limit Coverage

    Ambien, Ambien CR, Lunesta, and Rozerem
    25-day limit30 tablets
    75-day limit90 tablets
    Zolpidem tartrate capsules
    25-day limit30 capsules
    75-day limit90 capsules
    Zaleplon
    25-day limit60 capsules
    Policy Summary
    PayerCVS Caremark
    PolicyInsomnia Agents Post-Limit Prior Authorization Criteria
    Policy CodePolicy 201-J
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor continuation therapy, document a positive response to treatment, assess the need for continued therapy, and address contributing factors to insomnia.
    SourceLink
    On This Page
    Coverage CriteriaProvider ActionsPolicy BackgroundInitial TherapyContinuation TherapyQuantity Limits and Post-Limit Coverage
    Denial Risk

    No Post-Limit Benzodiazepine Quantities

    No post-limit quantities will be available for the specified benzodiazepines because data do not support their long-term use for insomnia management.

    • Doral
    • Estazolam
    • Flurazepam
    • Halcion
    • Restoril
    Note

    Excluded Products

    Edluar, zolpidem tartrate sublingual tablets (generic Intermezzo), ZolpiMist, Belsomra, Dayvigo, and Quviviq are outside these criteria. Refer requests for these products to the applicable prior authorization criteria.

    • Refer Edluar, generic Intermezzo, and ZolpiMist to the Insomnia (zolpidem sublingual, oral spray) criteria.
    • Refer Belsomra, Dayvigo, and Quviviq to the Insomnia (Belsomra, Dayvigo, Quviviq) criteria.
    Denial Risk

    Quantity Limits

    Quantity limits apply to the products below. Requests exceeding the applicable limits may be denied; refill-processing windows are incorporated into the 25-day and 75-day periods.

    • Ambien, Ambien CR, Lunesta, and Rozerem: 30 tablets per 25 days or 90 tablets per 75 days.
    • Zolpidem tartrate capsules: 30 capsules per 25 days or 90 capsules per 75 days.
    • Zaleplon: 60 capsules per 25 days or 180 capsules per 75 days.
    • The 25-day duration applies to a 30-day fill period; the 75-day duration applies to a 90-day fill period.

    Authorization may be granted when the requested drug is being prescribed for insomnia and all continuation criteria are met.

    Continuation therapy

    • Positive response: The patient has achieved or maintained a positive response to treatment from baseline.
    • Need assessed: The patient's need for continued therapy has been assessed.
    • Contributing factors addressed: Potential factors contributing to sleep disturbances continue to be addressed, including inappropriate sleep hygiene, sleep-environment issues, and treatable medical or psychiatric comorbid disorders.
    75-day limit180 capsules
    Doral, estazolam, flurazepam, Halcion, and Restoril
    Post-limit quantityNo post-limit quantities available
    Applies toDoral, estazolam, flurazepam, Halcion, and Restoril
    BasisThere is a lack of data supporting benzodiazepines for long-term management of insomnia
    Ambien, Ambien CR, Lunesta, and Rozerem
    25-day post-limit quantity30 tablets
    75-day post-limit quantity90 tablets
    Zolpidem tartrate capsules
    25-day post-limit quantity30 capsules
    75-day post-limit quantity90 capsules
    Zaleplon
    25-day post-limit quantity60 capsules
    75-day post-limit quantity180 capsules
    Doral, estazolam, flurazepam, Halcion, and Restoril
    Post-limit quantityNo post-limit quantities available
    Applies toDoral, estazolam, flurazepam, Halcion, and Restoril
    BasisThere is a lack of data supporting benzodiazepines for long-term management of insomnia